You are here: Home » Companies » News
Business Standard

US-based Amneal Pharmaceuticals acquires Puniska Healthcare for Rs 700 cr

Amneal on Tuesday said it has acquired the Ahmedabad-based drug firm

Amneal Pharmaceuticals | United States | pharmaceutical firms

Press Trust of India  |  New Delhi 

Pharma Sector, Pharma Companies
The acquisition also brings to the company approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialisation, Amneal said

US-based Inc on Tuesday said it has acquired Ahmedabad-based drug firm Puniska Healthcare Pvt Ltd for a total value of around Rs 700 crore.

The acquisition significantly enhances Amneal's injectables manufacturing infrastructure, capabilities, and capacity to support the US market and serve as a foundation for international markets, the company said in a statement.

Puniska includes a 293,000 square foot, manufacturing facility in Ahmedabad, with a number of sterile injectable production lines. Production capabilities include robotic, aseptic and lyophilize vial lines, emulsion line, and large-volume parenteral bag line, it added.

The acquisition also brings to the company approximately 550 Puniska employees with key capabilities in injectables manufacturing, R&D and commercialisation, Amneal said.

"This acquisition is a pivotal step that meaningfully enhances our injectables capabilities for the US market and enables international expansion, including in India, as we look to become a leading player in the global injectables market, Amneal Co-Chief Executive Officers Chirag and Chintu Patel said.

Puniska's ability to manufacture high volume and complex products will enable Amneal to build on its robust portfolio and pipeline and contribute to the rapid growth in injectables business, which it projects will more than double by 2025, they added.

Puniska acquisition has a total value of USD 93 million, or around Rs 700 crore rupees, Amneal said. Dhinal Shah Associates served as advisor to this transaction, it added.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

First Published: Tue, November 09 2021. 22:02 IST